361 related articles for article (PubMed ID: 17667795)
1. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
2. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
3. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
4. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
7. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio.
Ohara K; Tanabu S; Yoshida K; Ishibashi K; Ikemoto K; Shibuya H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):945-9. PubMed ID: 14499311
[TBL] [Abstract][Full Text] [Related]
8. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
9. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
Bozina N; Jovanović N; Lovrić M; Medved V
Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
[TBL] [Abstract][Full Text] [Related]
11. CYP 2D6 polymorphism and antipsychotic therapy.
Plesnicar BK; Dolzan V; Zalar B
Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
13. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
14. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio.
Ohara K; Tanabu S; Ishibashi K; Ikemoto K; Yoshida K; Shibuya H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):347-50. PubMed ID: 12691769
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
[TBL] [Abstract][Full Text] [Related]
16. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
17. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
18. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
[TBL] [Abstract][Full Text] [Related]
19. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
20. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
